Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer

Seminars in Cancer Biology

Volumn 16, Issue 6, 2006, Pages 444-451

  Nakamura, Hajime ^a   Masutani, Hiroshi ^b   Yodoi, Junji ^a,b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Redox; Thioredoxin; Thioredoxin binding protein 2

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYTOKINE; DITHIOTHREITOL; GLUTAREDOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MERCAPTOETHANOL; PEROXIREDOXIN; PROTEIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT THIOREDOXIN; THIOREDOXIN; THIOREDOXIN BINDING PROTEIN 2; THIOREDOXIN INHIBITOR; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CONTROL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CELL PROTECTION; CYTOSOL; DNA SYNTHESIS; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENETIC TRANSCRIPTION; HEPATITIS C; HOMEOSTASIS; HUMAN; IN VIVO STUDY; LEUKEMIA CELL; LEUKOCYTE; LIVER CELL CARCINOMA; MITOGENESIS; MONOCYTE; NEUTROPHIL; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS CANCER; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; REVIEW; SEQUENCE HOMOLOGY; UPREGULATION;

CARRIER PROTEINS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; THIOREDOXIN;

EID: 33751195309     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2006.09.001     Document Type: Review

References (87)

1. Laurent T.C., Moore E.C., and Reichard P. Enzymatic synthesis of deoxyribonucleotides IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 239 (1964) 3436-3444
2. Holmgren A. Thioredoxin. 6. The amino acid sequence of the protein from Escherichia coli B. Eur J Biochem 6 (1968) 475-484
3. Holmgren A. Thioredoxin. Ann Rev Biochem 54 (1985) 237-271
4. Moore E.C. A thioredoxin-thioredoxin reductase system from rat tumor. Biochem Biophys Res Commun 29 (1967) 264-268
5. Teshigawara K., Maeda M., Nishino K., et al. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 2 (1985) 17-26
6. Tagaya Y., Maeda Y., Mitsui A., et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 8 (1989) 757-764
7. Yodoi J., and Tursz T. ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV. Adv Cancer Res 57 (1991) 381-411
8. Yodoi J., and Uchiyama T. Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation. Immunol Today 13 (1992) 405-411
9. Giglione C., Boularot A., and Meinnel T. Protein N-terminal methionine excision. Cell Mol Life Sci 61 (2004) 1455-1474
10. Watson W.H., Pohl J., Montfort W.R., et al. Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif. J Biol Chem 278 (2003) 33408-33415
11. Ren X., Bjornstedt M., Shen B., Ericson M.L., and Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 32 (1993) 9701-9708
12. Andersen J.F., Sanders D.A., Gasdaska J.R., et al. Human thioredoxin homodimers: regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60→asparagine mutant. Biochemistry 36 (1997) 13979-13988
13. Fuchs J., Podda M., and Packer L. Series introduction (2004), Marcel Dekker, Inc., New York
14. Matsui M., Oshima M., Oshima H., et al. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178 (1996) 179-185
15. Saitoh M., Nishitoh H., Fujii M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. Embo J 17 (1998) 2596-2606
16. Nakamura H., Nakamura K., and Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 15 (1997) 351-369
17. Masutani H., Ueda S., and Yodoi J. The thioredoxin system in retroviral infection and apoptosis. Cell Death Differ 12 Suppl. 1 (2005) 991-998
18. Tanaka T., Hosoi F., Yamaguchi-Iwai Y., et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. Embo J 21 (2002) 1695-1703
19. Conrad M., Jakupoglu C., Moreno S.G., et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24 (2004) 9414-9423
20. Matsuo Y., Akiyama N., Nakamura H., et al. Identification of a novel thioredoxin related transmembrane protein. J Biol Chem 276 (2001) 10032-10038
21. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56 (1966) 72-77
22. Morand E.F., Leech M., and Bernhagen J. MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 5 (2006) 399-411
23. Kleemann R., Kapurniotu A., Frank R.W., et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280 (1998) 85-102
24. Kleemann R., Hausser A., Geiger G., et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408 (2000) 211-216
25. Hwang C.Y., Ryu Y.S., Chung M.S., et al. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene 23 (2004) 8868-8875
26. Kondo N., Ishii Y., Son A., et al. Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins. Immunol Lett 92 (2004) 143-147
27. Ishizaka K. IgE-binding factors and regulation of the IgE antibody response. Annu Rev Immunol 6 (1988) 513-534
28. Watarai H., Nozawa R., Tokunaga A., et al. Posttranslational modification of the glycosylation inhibiting factor (GIF) gene product generates bioactive GIF. Proc Natl Acad Sci USA 97 (2000) 13251-13256
29. Rundlof A.K., and Arner E.S. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6 (2004) 41-52
30. Rhee S.G., Chae H.Z., and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38 (2005) 1543-1552
31. Nishiyama A., Matsui M., Iwata S., et al. Identification of thioredoxin-binding protein-2/Vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274 (1999) 21645-21650
32. Wakasugi H., Rimsky L., Mahe Y., et al. Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as an growth factor. Proc Natl Acad Sci USA 84 (1987) 804-808
33. Wollman E.E., d'Auriol L., Rimsky L., et al. Cloning and expression of a cDNA for human thioredoxin. J Biol Chem 263 (1988) 15506-15512
34. Rosén A., Lundman P., Carlsson M., et al. a CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 7 (1995) 625-633
35. Silberstein D.S., McDonough S., Minkoff M.S., and Balcewicz S.M. Human eosinophil cytotoxicity-enhancing factor. Eosinophil-stimulating and dithiol reductase activities of biosynthetic (recombinant) species with COOH-terminal deletions. J Biol Chem 268 (1993) 9138-9142
36. Clarke F.M., Orozco C., Perkins A.V., et al. Identification of molecules involved in the 'early pregnancy factor' phenomenon. J Reprod Fertil 93 (1991) 525-539
37. Tagaya Y., Wakasugi H., Masutani H., et al. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction. Mol Immunol 27 (1990) 1279-1289
38. Wakasugi N., Tagaya Y., Wakasugi H., et al. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 87 (1990) 8282-8286
39. Nakamura H., Vaage J., Valen G., et al. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 24 (1998) 1176-1186
40. Billiet L., Furman C., Larigauderie G., et al. Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem 280 (2005) 40310-40318
41. Gasdaska J.R., Kirkpatrick D.L., Montfort W., et al. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation. Biochem Pharmacol 52 (1996) 1741-1747
42. Tonissen K., Wells J., Cock I., et al. Site-directed mutagenesis of human thioredoxin. Identification of cysteine 74 as critical to its function in the "early pregnancy factor" system. J Biol Chem 268 (1993) 22485-22489
43. Powis G., Oblong J.E., Gasdaska P.Y., et al. The thioredoxin/thioredoxin reductase redox system and control of cell growth. Oncol Res 6 (1994) 539-544
44. Pekkari K., Gurunath R., Arner E.S., and Holmgren A. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem 275 (2000) 37474-37480
45. Pekkari K., Avila-Carino J., Bengtsson A., et al. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood 97 (2001) 3184-3190
46. Pekkari K., and Holmgren A. Truncated thioredoxin: physiological functions and mechanism. Antioxid Redox Signal 6 (2004) 53-61
47. Pekkari K., Avila-Carino J., Gurunath R., et al. Truncated thioredoxin (Trx80) exerts unique mitogenic cytokine effects via a mechanism independent of thiol oxido-reductase activity. FEBS Lett 539 (2003) 143-148
48. Matsuda M., Masutani H., Nakamura H., et al. Protective activity of adult T cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J Immunol 147 (1991) 3837-3841
49. Nakamura H., Matsuda M., Furuke K., et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 42 (1994) 75-80
50. Kondo N., Ishii Y., Kwon Y.W., et al. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 172 (2004) 442-448
51. Schenk H., Vogt M., Droge W., and Schulze O.K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol 156 (1996) 765-771
52. Hori K., Hirashima M., Ueno M., et al. Regulation of eosinophil migration by adult T cell leukemia-derived factor. J Immunol 151 (1993) 5624-5630
53. Bertini R., Howard O.M., Dong H.F., et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 189 (1999) 1783-1789
54. Sahaf B., and Rosen A. Secretion of 10-kDa and 12-kDa thioredoxin species from blood monocytes and transformed leukocytes. Antioxid Redox Signal 2 (2000) 717-726
55. Nakamura H., De Rosa S.C., Yodoi J., et al. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci USA 98 (2001) 2688-2693
56. Nakamura H., Herzenberg L.A., Bai J., et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 98 (2001) 15143-15148
57. Pagliei S., Ghezzi P., Bizzarri C., et al. Thioredoxin specifically cross-desensitizes monocytes to MCP-1. Eur Cytokine Netw 13 (2002) 261-267
58. Bizzarri C., Holmgren A., Pekkari K., et al. Requirements for the different cysteines in the chemotactic and desensitizing activity of human thioredoxin. Antioxid Redox Signal 7 (2005) 1189-1194
59. Nakamura H., De Rosa S., Roederer M., et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 8 (1996) 603-611
60. Burke-Gaffney A., Callister M.E., and Nakamura H. Thioredoxin: friend or foe in human disease?. Trends Pharmacol Sci 26 (2005) 398-404
61. Sumida Y., Nakashima T., Yoh T., et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 33 (2000) 616-622
62. Miyazaki K., Noda N., Okada S., et al. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy 11 (1998) 277-288
63. Nakamura H., Bai J., Nishinaka Y., et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24 (2000) 53-60
64. Hoshino T., Nakamura H., Okamoto M., et al. Redox-active protein thioredoxin prevents proinflammatory cytokine-or bleomycin-induced lung injury. Am J Respir Crit Care Med 168 (2003) 1075-1083
65. Ueda S., Nakamura T., Yamada A., et al. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci (2006)
66. Yokomizo A., Ono M., Nanri H., et al. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55 (1995) 4293-4296
67. Sasada T., Iwata S., Sato N., et al. Redox control of resistance to cis diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97 (1996) 2268-2276
68. Powis G., and Montfort W.R. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41 (2001) 261-295
69. Chen K.S., and DeLuca H.F. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1219 (1994) 26-32
70. Junn E., Han S.H., Im J.Y., et al. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164 (2000) 6287-6295
71. Yamanaka H., Maehira F., Oshiro M., et al. A possible interaction of thioredoxin with VDUP1 in HeLa cells detected in a yeast two-hybrid system. Biochem Biophys Res Commun 271 (2000) 796-800
72. Butler L.M., Zhou X., Xu W.S., et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99 (2002) 11700-11705
73. Schulze P.C., De Keulenaer G.W., Yoshioka J., Kassik K.A., and Lee R.T. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 91 (2002) 689-695
74. Han S.H., Jeon J.H., Ju H.R., et al. VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22 (2003) 4035-4046
75. Joguchi A., Otsuka I., Minagawa S., et al. Overexpression of VDUP1 mRNA sensitizes HeLa cells to paraquat. Biochem Biophys Res Commun 293 (2002) 293-297
76. Nishinaka Y., Masutani H., Oka S., et al. Importin alpha1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/Vitamin D(3)-up-regulated protein 1. J Biol Chem 279 (2004) 37559-37565
77. Nishinaka Y., Nishiyama A., Masutani H., et al. Loss of thioredoxin-binding protein-2/Vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res 64 (2004) 1287-1292
78. Ikarashi M., Takahashi Y., Ishii Y., et al. Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res 22 (2002) 4045-4048
79. Tome M.E., Johnson D.B., Rimsza L.M., et al. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood 106 (2005) 3594-3601
80. Goldberg S.F., Miele M.E., Hatta N., et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 63 (2003) 432-440
81. Maeda M., Arima N., Daitoku Y., et al. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood 70 (1987) 1407-1411
82. Ahsan M.K., Masutani H., Yamaguchi Y., et al. Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene 25 (2006) 2181-2191
83. Oka S., Liu W., Masutani H., et al. Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. Faseb J 20 (2006) 121-123
84. Sheth S.S., Castellani L.W., Chari S., et al. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res 46 (2005) 123-134
85. Lee K.N., Kang H.S., Jeon J.H., et al. VDUP1 is required for the development of natural killer cells. Immunity 22 (2005) 195-208
86. Oka S., Masutani H., Liu W., et al. Thioredoxin-binding protein-2-like inducible membrane protein is a novel Vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology 147 (2006) 733-743
87. Yamamoto Y., Sakamoto M., Fujii G., et al. Cloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma. Clin Cancer Res 7 (2001) 297-303